Mechanisms of action of intravenous immunoglobulin

Transfusion and Apheresis Science

Volumn 56, Issue 1, 2017, Pages 45-49

  Chaigne, Benjamin ^a,b   Mouthon, Luc ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

Author keywords

Auto immune diseases; Immunomodulation; Intravenous immunoglobulins; Substitution

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CHEMICAL COMPOSITION; DENDRITIC CELL; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; IMMUNOMODULATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; PHYSIOLOGY;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION;

EID: 85011072541     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.12.017     Document Type: Review

References (37)

1. [1] Imbach, P., Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly, 142, 2012, w13593, 10.4414/smw.2012.13593.
2. [2] Valverde, J.L., Rare diseases: focus on rare plasma related disorders, vol. 4, 2009.
3. [3] World Health Organization Recommendations for the production, control and regulation of human plasma for fractionation (Annex 4). WHO Tech Rep Ser, 2007, 189–264.
4. [4] Dhainaut, F., Guillaumat, P.-O., Dib, H., Perret, G., Sauger, A., de Coupade, C., et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang 104 (2013), 115–126, 10.1111/j.1423-0410.2012.01648.x.
5. [5] Bayry, J., Lacroix-Desmazes, S., Donkova-Petrini, V., Carbonneil, C., Misra, N., Lepelletier, Y., et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 101 (2004), 14210–14215, 10.1073/pnas.0402183101.
6. [6] Bayry, J., Fournier, E.M., Maddur, M.S., Vani, J., Wootla, B., Sibéril, S., et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 36 (2011), 9–15, 10.1016/j.jaut.2010.09.006.
7. [7] Guilpain, P., Chanseaud, Y., Tamby, M.C., Larroche, C., Guillevin, L., Kaveri, S.V., et al. Immunomodulatory effects of intravenous immunoglobulins. Presse Med. Paris Fr 1983 33 (2004), 1183–1194.
8. [8] Spalter, S., Kaveri, S.V., Kazatchkine, M.D., Anti-idiotypes to autoantibodies in therapeutic preparations of normal polyspecific human IgG (IVIg). Shoenfeld, Y., Kennedy, R.C., Ferrone, S., (eds.) Idiotypes in medicine: autoimmunity, infection and cancer, 1997, Elsevier Science, 217–225.
9. [9] Lutz, H.U., Späth, P.J., Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation. Clin Rev Allergy Immunol 29 (2005), 207–212, 10.1385/CRIAI:29:3:207.
10. [10] Basta, M., Van Goor, F., Luccioli, S., Billings, E.M., Vortmeyer, A.O., Baranyi, L., et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9 (2003), 431–438, 10.1038/nm836.
11. [11] Basta, M., Illa, I., Dalakas, M.C., Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 71 (1996), 227–229.
12. [12] Basta, M., Dalakas, M.C., High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94 (1994), 1729–1735, 10.1172/JCI117520.
13. [13] Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26 (2008), 513–533, 10.1146/annurev.immunol.26.021607.090232.
14. [14] Yu, Z., Lennon, V.A., Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340 (1999), 227–228, 10.1056/NEJM199901213400311.
15. [15] Samuelsson, A., Towers, T.L., Ravetch, J.V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001), 484–486, 10.1126/science.291.5503.484.
16. [16] Kaneko, Y., Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673, 10.1126/science.1129594.
17. [17] Guhr, T., Bloem, J., Derksen, N.I.L., Wuhrer, M., Koenderman, A.H.L., Aalberse, R.C., et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One, 6, 2011, e21246, 10.1371/journal.pone.0021246.
18. [18] Leontyev, D., Katsman, Y., Ma, X.-Z., Miescher, S., Käsermann, F., Branch, D.R., Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion (Paris) 52 (2012), 1799–1805, 10.1111/j.1537-2995.2011.03517.x.
19. [19] Campbell, I.K., Miescher, S., Branch, D.R., Mott, P.J., Lazarus, A.H., Han, D., et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol Baltim Md 1950 192 (2014), 5031–5038, 10.4049/jimmunol.1301611.
20. [20] Käsermann, F., Boerema, D.J., Rüegsegger, M., Hofmann, A., Wymann, S., Zuercher, A.W., et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One, 7, 2012, e37243, 10.1371/journal.pone.0037243.
21. [21] Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003), 758–765, 10.1182/blood-2002-05-1447.
22. [22] Wiedeman, A.E., Santer, D.M., Yan, W., Miescher, S., Käsermann, F., Elkon, K.B., Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum 65 (2013), 2713–2723, 10.1002/art.38082.
23. [23] Sharma, M., Schoindre, Y., Hegde, P., Saha, C., Maddur, M.S., Stephen-Victor, E., et al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci Rep, 4, 2014, 5672, 10.1038/srep05672.
24. [24] Anthony, R.M., Kobayashi, T., Wermeling, F., Ravetch, J.V., Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475 (2011), 110–113, 10.1038/nature10134.
25. [25] Maddur, M.S., Vani, J., Hegde, P., Lacroix-Desmazes, S., Kaveri, S.V., Bayry, J., Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 127 (2011), 823–830, 10.1016/j.jaci.2010.12.1102 e1–e7.
26. [26] Maddur, M.S., Kaveri, S.V., Bayry, J., Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 10 (2011), 809–810, 10.1016/j.autrev.2011.02.007.
27. [27] Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., Toda, M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol Baltim Md 1950 155 (1995), 1151–1164.
28. [28] Othy, S., Hegde, P., Topçu, S., Sharma, M., Maddur, M.S., Lacroix-Desmazes, S., et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol Baltim Md 1950 190 (2013), 4535–4541, 10.4049/jimmunol.1201965.
29. [29] Othy, S., Topçu, S., Saha, C., Kothapalli, P., Lacroix-Desmazes, S., Käsermann, F., et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol 44 (2014), 2059–2063, 10.1002/eji.201444440.
30. [30] Chong, W.P., Ling, M.T., Liu, Y., Caspi, R.R., Wong, W.M., Wu, W., et al. Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis. PLoS One, 8, 2013, e60862, 10.1371/journal.pone.0060862.
31. [31] Bayry, J., Mouthon, L., Kaveri, S.V., Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol 39 (2012), 450–451, 10.3899/jrheum.111123.
32. [32] Trinath, J., Hegde, P., Sharma, M., Maddur, M.S., Rabin, M., Vallat, J.-M., et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122 (2013), 1419–1427, 10.1182/blood-2012-11-468264.
33. [33] Tjon, A.S.W., Tha-In, T., Metselaar, H.J., van Gent, R., van der Laan, L.J.W., Groothuismink, Z.M.A., et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 173 (2013), 259–267, 10.1111/cei.12102.
34. [34] Tackenberg, B., Jelcic, I., Baerenwaldt, A., Oertel, W.H., Sommer, N., Nimmerjahn, F., et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 106 (2009), 4788–4792, 10.1073/pnas.0807319106.
35. [35] Nikolova, K.A., Tchorbanov, A.I., Djoumerska-Alexieva, I.K., Nikolova, M., Vassilev, T.L., Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells. Immunol Cell Biol 87 (2009), 529–533, 10.1038/icb.2009.36.
36. [36] Séité, J.-F., Guerrier, T., Cornec, D., Jamin, C., Youinou, P., Hillion, S., TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun 37 (2011), 190–197, 10.1016/j.jaut.2011.05.014.
37. [37] Schwab, I., Seeling, M., Biburger, M., Aschermann, S., Nitschke, L., Nimmerjahn, F., B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol 42 (2012), 3302–3309, 10.1002/eji.201242710.